Celera initiated by Global Crown at overweight

Applera Corp.-Celera Genomics Group coverage was initiated by Global Crown Capital analyst Kate Winkler at an overweight rating. Celera's science is frustratingly slow, but Global Crown sees Celera, through innovations in diagnostics and therapeutics as a key architect of 21st century medicine to treat cancer, autoimmune and inflammatory diseases. Celera shares Tuesday climbed $0.13, or 1.15%, to $11.40 on volume of 212,400 shares versus the three-month running average of 295,009 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.